AOD-9604 vs CJC-1295

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 is a synthetic fragment of the human growth hormone molecule, corresponding to amino acids 176–191 of the C-terminus. It is researched specifically for its lipolytic properties and is considered a lower-risk alternative to full growth hormone analogues for body composition research, given its apparent lack of effect on insulin sensitivity or IGF-1 levels.

CJC-1295 binds to and activates pituitary GHRH receptors, stimulating pulsatile GH secretion. The DAC modification enables covalent binding to albumin, dramatically extending the active peptide half-life. This sustained GH pulse pattern is intended to mimic physiological GH release more closely than shorter-acting GHRH analogues.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) form binds to albumin in the bloodstream, extending its half-life to several days and enabling sustained elevation of GH and IGF-1 levels. It is commonly researched alongside GHRP peptides for body composition and recovery outcomes.